On September 5, ImmuneOnco Biopharmaceuticals (Shanghai) Inc.  ("ImmuneOnco", stock code："01541.HK") was successfully listed on the Main Board of the Hong Kong Stock Exchange.
ImmuneOnco is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. ImmuneOnco is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems.Its product pipeline includes 14 drug candidates featuring a comprehensive portfolio of innate immunity-based assets, eight of which are in the clinical stage.
JunHe and Cooley are the Company's legal advisors in China and Hong Kong respectively;
Jingtian & Gongcheng and Kirkland & Ellis are the underwriters' legal advisors in China and Hong Kong respectively.